JPMorgan Chase & Co. Has $6.65 Million Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

JPMorgan Chase & Co. boosted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 212.6% in the third quarter, Holdings Channel reports. The firm owned 140,491 shares of the company’s stock after purchasing an additional 95,547 shares during the quarter. JPMorgan Chase & Co.’s holdings in Kymera Therapeutics were worth $6,649,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics during the 3rd quarter worth about $61,000. Quarry LP bought a new stake in Kymera Therapeutics during the third quarter worth about $95,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new position in Kymera Therapeutics during the second quarter valued at approximately $139,000. Finally, XTX Topco Ltd acquired a new position in shares of Kymera Therapeutics during the 2nd quarter worth approximately $201,000.

Analysts Set New Price Targets

Several equities research analysts have recently commented on KYMR shares. Truist Financial reissued a “buy” rating and issued a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. UBS Group cut their price target on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Morgan Stanley boosted their price objective on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. Stephens initiated coverage on shares of Kymera Therapeutics in a research note on Monday, November 18th. They issued an “overweight” rating and a $65.00 target price for the company. Finally, BTIG Research assumed coverage on Kymera Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target on the stock. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $55.38.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares in the company, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $43.56 on Thursday. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -18.62 and a beta of 2.19. The stock’s fifty day moving average price is $43.57 and its two-hundred day moving average price is $44.25. Kymera Therapeutics, Inc. has a one year low of $26.34 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter in the previous year, the business posted ($0.90) earnings per share. Kymera Therapeutics’s quarterly revenue was down 20.9% on a year-over-year basis. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.